Open AccessSmall bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy
Author(s) -
Kenichi Nomura,
Koichi Tomikashi,
Yosuke Matsumoto,
Naohisa Yoshida,
Takashi Okuda,
Chohei Sakakura,
Shoji Mitsufuji,
Shigeo Horiike,
Hisakazu Yamagishi,
Takeshi Okanoue,
Masafumi Taniwaki
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i28.4443
Subject(s) - medicine , rituximab , lymphoma , pathological , laparotomy , adjuvant therapy , gastroenterology , jejunum , adjuvant , diffuse large b cell lymphoma , bowel obstruction , surgery , chemotherapy
A 44-year-old man was referred to our hospital with intermittent abdominal pain. Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction. A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall. Some mesenteric lymph nodes were swollen. Pathological examination was defined. We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses. Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m2. Four cycles were performed every 6 mo and he remained CR. Rituximab may be effective as adjuvant therapy.